Retatrutide
Aliases: LY3437943 · triple hormone receptor agonist
Retatrutide is a linear peptide targeting GLP-1R, GIPR, Glucagon receptor, developed by Eli Lilly for multiple indications. As of Aug 15, 2024, its highest verified stage is Phase 3.
Phase 3· verified Aug 15, 2024
Identity
- Generic name
- retatrutide
- Brand names
- —
- Development codes
- LY3437943
- Sponsor / originator
- Eli Lilly
- Targets
- GLP-1RGIPRGlucagon receptor
- Route / formulation
- Subcutaneous injection
Development timeline
- Phase 3· Obesity· Global
As of Aug 15, 2024 · Confidence: high
Source: A study of retatrutide (LY3437943) in participants with obesityTRIUMPH phase 3 program ongoing for obesity.
- Phase 2· NASH/MASH· Global
As of Aug 15, 2024 · Confidence: medium
Source: A study of retatrutide (LY3437943) in participants with obesityExploratory NASH cohorts included in broader retatrutide program.
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| NCT05567796 | Phase 3 | Recruiting | 3000 | Dec 1, 2026 |
Readouts
View all →Next catalysts
View all →Sources
- registryprimary record
A study of retatrutide (LY3437943) in participants with obesity
Eli Lilly and Company · ClinicalTrials.gov · Sep 8, 2022 · NCT05567796